© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 161 Farringdon Rd, London EC1R 3AL. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions | Cookies

Hong Kong SAR

  • Hong Kong is exploring the possibility of getting in on the craze around special purpose acquisition companies (Spac), which has begun to gain ground in Asia this year.
  • Online car marketplace Autohome has launched the roadshow for a secondary listing in Hong Kong. The float of new and existing stock could raise up to HK$7.6bn ($983.2m).
  • Hang Seng Indexes Co is planning to double the stocks in its flagship index, a move that will better represent the increasing number of Chinese companies on the bourse.
  • Gome Retail Holdings, an electrical appliance retailer, has raised HK$4.45bn ($573.5m) after selling a chunk of shares in a top-up placement.
  • Blank cheque firm Magnum Opus Acquisition has set in motion a $200m New York Stock Exchange IPO, filing paperwork with the US regulator on Monday.
  • JP Morgan has stepped down from its position as sponsor on healthcare platform WeDoctor’s planned Hong Kong IPO, according to a source familiar with the matter.
  • Malaysian rubber glove manufacturer Top Glove Corp is aiming to raise up to HK$14.95bn ($1.93bn) from a dual primary listing in Hong Kong.
  • Chinese company Gangfeng Lithium Co is gearing up to tap equity investors for as much as HK$4.9bn ($632m) from a private placement of its Hong Kong-listed shares, as it looks to raise money to expand some of its projects and investments.
  • Cheerwin Group, a Chinese company that makes personal and household care products, has thrown open its up to HK$3.1bn ($400m) Hong Kong IPO, testing investor appetite following a slump in the benchmark index this week over a planned increase in the stamp duty paid on stock trading.
  • A Covid baby boom has come to capital markets.
  • Hong Kong's Castle Peak Power Co sold its third energy transition bond on Wednesday, raising $300m and solidifying its leadership in the sector in Asia.
  • SciClone Pharmaceuticals bagged HK$2.18bn ($281.2m) after pricing its IPO high on the back of storming demand from institutional and retail investors, according to sources close to the deal.